Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 594

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 594
---
4 consisted of payments made to HCR under the royalty purchase and sale agreement of approximately $2.0 million. Net cash provided by financing activities for the nine months ended September 30, 2023 consisted of proceeds of $1.1 million from the sales of common stock under Cara’s open market sales agreement and proceeds of $0.6 million received from the exercise of stock options. For the Years Ended December 31, 2023 and 2022 The following is a summary of the net cash flows provided by (used in) Cara’s operating, investing and financing activities for the years ended December 31, 2023 and 2022:

| ​                                                                     
 ​                                                                     | ​ 
 ​ | ​ 
 ​ | Year Ended December 31,     
 2023                        |   |         |   | ​ | ​ | 2022 |   |         |   | ​ 
 ​ |
|:----------------------------------------------------------------------|:--|:--|:----------------------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| ​                                                                     | ​ | ​ | Dollar amounts in thousands |   |         |   |   |   |      |   |         |   | ​ |
| Net cash used in operating activities                                 | ​ | ​ | ​                           | $ | -92,078 | ​ | ​ | ​ | ​    | $ | -78,730 | ​ | ​ |
| Net cash provided by (used in) investing activities                   | ​ | ​ | ​                           | ​ |  43,461 | ​ | ​ | ​ | ​    | ​ | 128,707 | ​ | ​ |
| Net cash provided by financing activities                             | ​ | ​ | ​                           | ​ |  38,151 | ​ | ​ | ​ | ​    | ​ |     311 | ​ | ​ |
| Net (decrease) increase in cash, cash equivalents and restricted cash | ​ | ​ | ​                           | $ | -10,466 | ​ | ​ | ​ | ​    | $ |  50,288 | ​ | ​ |

Net cash used in operating activities Net cash used in operating activities for the year ended December 31, 2023 consisted primarily of a net loss of $118.5 million, partially offset by a $16.3 million cash inflow from net non-cash charges and a

340

TABLE OF CONTENTS

$10